2010

2009

2008

2007

Santa Clara, CA, June 16, 2010 — Relypsa, Inc., today announced the appointment of Claire Lockey to the position of Vice President, Regulatory Affairs. 

Ms. Lockey brings more than thirty-five years of experience in the pharmaceutical industry, including more than twenty-five years specializing in regulatory affairs.  In her new role, Ms. Lockey will be responsible for overseeing Relypsa’s regulatory affairs, quality assurance and related project management, reporting to the company’s President, Gerrit Klaerner, Ph.D.  She will initially focus on the clinical development of Relypsa’s lead product candidate, RLY5016, a potassium binder for the management of hyperkalemia.

“We are pleased to welcome Claire to the Relypsa team at a crucial time for RLY5016 as we prepare for late-stage development activities.  Over the course of her career, she has achieved a successful track record in shepherding important products through all phases of clinical evaluation and regulatory approvals from the U.S. Food and Drug Administration,” said Dr. Klaerner.  “Specifically, Claire’s extensive experience in developing products for the treatment of cardio-renal diseases will be highly valued as we focus on positioning RLY5016 to benefit patients with heart failure and chronic kidney disease.”

Ms. Lockey joins Relypsa from Fibrogen, Inc. where she served as Vice President, Regulatory Affairs.  While there, she managed all of the company’s regulatory submissions, quality assurance and compliance activities, including oversight of multiple product candidates.  Prior, Ms. Lockey held executive positions at other biopharmaceutical companies including Titan Pharmaceuticals, Layton Bioscience, Connetics Corporation and Gore Hybrid Technologies.  Earlier in her career she consulted for ten years with Synergia, an organization focused on the regulatory and clinical development of new health care products.  Ms. Lockey earned her B.A. in Biology at Boston University.

About Relypsa, Inc.
Relypsa, Inc. is a privately-held, development-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases.  Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to the discovery of additional product candidates through use of its proprietary polymer platform.  Relypsa has raised a total of $43 million in a Series A round from leading venture capital firms, including 5AM Ventures, Amgen, Delphi Ventures, Mediphase Ventures, Sprout and NLV Partners.  For additional information, please see the Relypsa website at www.relypsa.com.

CONTACT: Reypsa, Inc.
Gerrit Klaerner, Ph.D
President and COO
PR "at" relypsa.com